Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03409614 · OUTCOME

Part 1: Best Overall Response (BOR) Per IRC

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 32 months

What was measured

BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.

Analysis population: Part 1 participants only

Groups in this outcome

Part 1: Cemiplimab + Chemotherapy

Participants received cemiplimab plus platinum-based doublet chemotherapy

Part 1: Cemiplimab+AbbrevChemo+Ipilimumab

Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab

Part 1: Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: Cemiplimab + Chemotherapy108
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab109
Part 1: Chemotherapy106

Reported measurements

Source class 1

Complete Response (CR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy3Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab5Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy2Not reportedNot reportedNot reportedNot reported

Partial Response (PR)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy41Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab35Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy28Not reportedNot reportedNot reportedNot reported

Stable Disease (SD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy41Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab44Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy51Not reportedNot reportedNot reportedNot reported

Progressive Disease (PD)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy4Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab15Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy8Not reportedNot reportedNot reportedNot reported

Non-CR / Non-PD

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy3Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab0Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy1Not reportedNot reportedNot reportedNot reported

Not Evaluable (NE)

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy16Not reportedNot reportedNot reportedNot reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab10Not reportedNot reportedNot reportedNot reported
Part 1: Chemotherapy16Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        5
      3. group Id
        OG002
        value
        2
      title
      Complete Response (CR)
    2. measurements
      1. group Id
        OG000
        value
        41
      2. group Id
        OG001
        value
        35
      3. group Id
        OG002
        value
        28
      title
      Partial Response (PR)
    3. measurements
      1. group Id
        OG000
        value
        41
      2. group Id
        OG001
        value
        44
      3. group Id
        OG002
        value
        51
      title
      Stable Disease (SD)
    4. measurements
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        15
      3. group Id
        OG002
        value
        8
      title
      Progressive Disease (PD)
    5. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        1
      title
      Non-CR / Non-PD
    6. measurements
      1. group Id
        OG000
        value
        16
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        16
      title
      Not Evaluable (NE)
denoms
  1. counts
    1. group Id
      OG000
      value
      108
    2. group Id
      OG001
      value
      109
    3. group Id
      OG002
      value
      106
    units
    Participants
description
BOR was defined as the best overall response as determined by the IRC per RECIST 1.1, between the date of randomization and the date of first documented tumor progression or the date of subsequent anti-cancer therapy, whichever occurred earlier.
groups
  1. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy
    id
    OG000
    title
    Part 1: Cemiplimab + Chemotherapy
  2. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
    id
    OG001
    title
    Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
  3. description
    Participants received platinum-based doublet chemotherapy
    id
    OG002
    title
    Part 1: Chemotherapy
param Type
COUNT_OF_PARTICIPANTS
population Description
Part 1 participants only
reporting Status
POSTED
time Frame
Up to 32 months
title
Part 1: Best Overall Response (BOR) Per IRC
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice